Stability of fluoroquinolone resistance in Streptococcus pneumoniae clinical isolates and laboratory-derived mutants

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 2, 2005, Pages 846-848

  Smith Adam, Heather J ^a,b   Nichol, Kimberly A ^b   Hoban, Daryl J ^a,b   Zhanel, George G ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM MUTANT; DRUG EXCRETION; GENE MUTATION; GENETIC STABILITY; GENOTYPE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DNA GYRASE; DNA TOPOISOMERASES, TYPE II, BACTERIAL; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FLUOROQUINOLONES; GENOTYPE; HUMANS; PHENOTYPE; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 12944300984     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.2.846-848.2005     Document Type: Article

References (12)

1. Bast, D., D. E. Low, C. L. Duncan, L. Kilburn, L. A. Mandell, R. J. Davidson, and J. C. S. deAzavedo. 2000. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob. Agents Chemother. 44:3049-3054.
2. Brueggemann, A. B., S. L. Coffman, P. Rhomberg, H. Huynh, L. Almer, A. Nilius, R. Flamm, and G. V. Doern. 2002. Fluoroquinolone resistance in Streptococcus pneumoniae in the United States since 1994-1995. Antimicrob. Agents Chemother. 46:680-688.
3. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
4. Ho, P. L., R. W. H. Yung, D. N. C. Tsang, T. L. Que, M. Ho, W. H. Seto, T. K. Ng, W. C. Yam, and W. W. S. Ng. 2001. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J. Antimicrob. Chemother. 48:659-665.
5. Morrissey, I., and J. George. 1999. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins. Antimicrob. Agents Chemother. 43:2579-2585.
6. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement, M100-S12. National Committee for Clinical Laboratory Standards, Wayne, Pa.
7. Nichol, K., G. G. Zhanel, and D. J. Hoban. 2003. Molecular epidemiology of penicillin-resistant and ciprofloxacin-resistant Streptococcus pneumoniae in Canada. Antimicrob. Agents Chemother. 47:804-808.
8. Piddock, L. J., M. M. Johnson, S. Simjee, and L. Pumbwe. 2002. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46:808-812.
9. Smith, H. J., M. Walters, T Hisanaga, G. G. Zhanel, and D. J. Hoban. 2004. Mutant prevention concentrations of single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or isolates containing ParC or GyrA mutations in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48:3954-3958.
10. Zhanel, G. G., K. Ennis, L. Vercaigne, A. Walkty, J. Embil, A. Gin, and D. J. Hoban. 2002. A critical review of the new fluoroquinolones: focus on respiratory infections. Drugs 62:13-59.
11. Zhanel, G. G., L. Palatnick, K. Nichol, T. Bellyou, D. Low, The CROSS Study Group, and D. J. Hoban. 2003. Five-year incidence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of the Canadian Respiratory Organism Susceptibility Study. 1997-2002. Antimicrob. Agents Chemother. 47:1867-1874.
12. Zhanel, G. G., A. Walkty, K. Nichol, H. Smith, and D. J. Hoban. 2003. Molecular characterization of resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagn. Microbiol. Infect. Dis. 45:63-67.